The global Polycystic Ovary Syndrome (PCOS) Drugs market was valued at US$ 3317.8 million in 2023 and is anticipated to reach US$ 4502.7 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.

Polycystic Ovary Syndrome (PCOS) Drugs Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Polycystic Ovary Syndrome (PCOS) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Polycystic Ovary Syndrome (PCOS) Drugs.

Report Scope

The Polycystic Ovary Syndrome (PCOS) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Polycystic Ovary Syndrome (PCOS) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Polycystic Ovary Syndrome (PCOS) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Polycystic Ovary Syndrome (PCOS) Drugs Market Report

Report Metric	Details
Report Name	Polycystic Ovary Syndrome (PCOS) Drugs Market
Accounted market size in 2023	US$ 3317.8 million
Forecasted market size in 2030	US$ 4502.7 million
CAGR	4.4%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Oral Contraceptives Antiandrogens Insulin-Sensitizing Agent Antidepressant Anti-Obesity
Segment by Application	Hospital Clinic
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Polycystic Ovary Syndrome (PCOS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Polycystic Ovary Syndrome (PCOS) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Polycystic Ovary Syndrome (PCOS) Drugs Market growing?

Ans: The Polycystic Ovary Syndrome (PCOS) Drugs Market witnessing a CAGR of 4.4% during the forecast period 2024-2030.

What is the Polycystic Ovary Syndrome (PCOS) Drugs Market size in 2030?

Ans: The Polycystic Ovary Syndrome (PCOS) Drugs Market size in 2030 will be US$ 4502.7 million.

Who are the main players in the Polycystic Ovary Syndrome (PCOS) Drugs Market report?

Ans: The main players in the Polycystic Ovary Syndrome (PCOS) Drugs Market are Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc.

What are the Application segmentation covered in the Polycystic Ovary Syndrome (PCOS) Drugs Market report?

Ans: The Applications covered in the Polycystic Ovary Syndrome (PCOS) Drugs Market report are Hospital, Clinic

What are the Type segmentation covered in the Polycystic Ovary Syndrome (PCOS) Drugs Market report?

Ans: The Types covered in the Polycystic Ovary Syndrome (PCOS) Drugs Market report are Oral Contraceptives, Antiandrogens, Insulin-Sensitizing Agent, Antidepressant, Anti-Obesity

1 Polycystic Ovary Syndrome (PCOS) Drugs Market Overview

1.1 Product Overview and Scope of Polycystic Ovary Syndrome (PCOS) Drugs

1.2 Polycystic Ovary Syndrome (PCOS) Drugs Segment by Type

1.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Oral Contraceptives

1.2.3 Antiandrogens

1.2.4 Insulin-Sensitizing Agent

1.2.5 Antidepressant

1.2.6 Anti-Obesity

1.3 Polycystic Ovary Syndrome (PCOS) Drugs Segment by Application

1.3.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Value by Application: (2024-2030)

1.3.2 Hospital

1.3.3 Clinic

1.4 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size Estimates and Forecasts

1.4.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue 2019-2030

1.4.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales 2019-2030

1.4.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Polycystic Ovary Syndrome (PCOS) Drugs Market Competition by Manufacturers

2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Polycystic Ovary Syndrome (PCOS) Drugs Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs, Product Type & Application

2.7 Polycystic Ovary Syndrome (PCOS) Drugs Market Competitive Situation and Trends

2.7.1 Polycystic Ovary Syndrome (PCOS) Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Polycystic Ovary Syndrome (PCOS) Drugs Players Market Share by Revenue

2.7.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Polycystic Ovary Syndrome (PCOS) Drugs Retrospective Market Scenario by Region

3.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region: 2019-2030

3.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region: 2019-2024

3.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region: 2025-2030

3.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region: 2019-2030

3.3.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region: 2019-2024

3.3.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region: 2025-2030

3.4 North America Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country

3.4.1 North America Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2019-2030)

3.4.3 North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country

3.5.1 Europe Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2019-2030)

3.5.3 Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2019-2030)

3.6.3 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country

3.7.1 Latin America Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2019-2030)

3.7.3 Latin America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2019-2030)

4.1.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2019-2024)

4.1.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2025-2030)

4.1.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Type (2019-2030)

4.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type (2019-2030)

4.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type (2019-2024)

4.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type (2025-2030)

4.2.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2019-2030)

5.1.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2019-2024)

5.1.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2025-2030)

5.1.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Application (2019-2030)

5.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application (2019-2030)

5.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application (2019-2024)

5.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application (2025-2030)

5.2.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Sanofi

6.1.1 Sanofi Corporation Information

6.1.2 Sanofi Description and Business Overview

6.1.3 Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.1.5 Sanofi Recent Developments/Updates

6.2 Novartis AG

6.2.1 Novartis AG Corporation Information

6.2.2 Novartis AG Description and Business Overview

6.2.3 Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.2.5 Novartis AG Recent Developments/Updates

6.3 Teva Pharmaceutical Industries Limited

6.3.1 Teva Pharmaceutical Industries Limited Corporation Information

6.3.2 Teva Pharmaceutical Industries Limited Description and Business Overview

6.3.3 Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.3.5 Teva Pharmaceutical Industries Limited Recent Developments/Updates

6.4 Addex Therapeutics Ltd.

6.4.1 Addex Therapeutics Ltd. Corporation Information

6.4.2 Addex Therapeutics Ltd. Description and Business Overview

6.4.3 Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.4.5 Addex Therapeutics Ltd. Recent Developments/Updates

6.5 BIOCAD

6.5.1 BIOCAD Corporation Information

6.5.2 BIOCAD Description and Business Overview

6.5.3 BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.5.5 BIOCAD Recent Developments/Updates

6.6 Merck KGaA

6.6.1 Merck KGaA Corporation Information

6.6.2 Merck KGaA Description and Business Overview

6.6.3 Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.6.5 Merck KGaA Recent Developments/Updates

6.7 AstraZeneca plc.

6.6.1 AstraZeneca plc. Corporation Information

6.6.2 AstraZeneca plc. Description and Business Overview

6.6.3 AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.7.5 AstraZeneca plc. Recent Developments/Updates

6.8 Bristol Myers Squibb Co.

6.8.1 Bristol Myers Squibb Co. Corporation Information

6.8.2 Bristol Myers Squibb Co. Description and Business Overview

6.8.3 Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.8.5 Bristol Myers Squibb Co. Recent Developments/Updates

6.9 Ferring Pharmaceuticals, Inc.

6.9.1 Ferring Pharmaceuticals, Inc. Corporation Information

6.9.2 Ferring Pharmaceuticals, Inc. Description and Business Overview

6.9.3 Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.9.5 Ferring Pharmaceuticals, Inc. Recent Developments/Updates

6.10 Crinetics Pharmaceuticals, Inc.

6.10.1 Crinetics Pharmaceuticals, Inc. Corporation Information

6.10.2 Crinetics Pharmaceuticals, Inc. Description and Business Overview

6.10.3 Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio

6.10.5 Crinetics Pharmaceuticals, Inc. Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Polycystic Ovary Syndrome (PCOS) Drugs Industry Chain Analysis

7.2 Polycystic Ovary Syndrome (PCOS) Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Polycystic Ovary Syndrome (PCOS) Drugs Production Mode & Process

7.4 Polycystic Ovary Syndrome (PCOS) Drugs Sales and Marketing

7.4.1 Polycystic Ovary Syndrome (PCOS) Drugs Sales Channels

7.4.2 Polycystic Ovary Syndrome (PCOS) Drugs Distributors

7.5 Polycystic Ovary Syndrome (PCOS) Drugs Customers

8 Polycystic Ovary Syndrome (PCOS) Drugs Market Dynamics

8.1 Polycystic Ovary Syndrome (PCOS) Drugs Industry Trends

8.2 Polycystic Ovary Syndrome (PCOS) Drugs Market Drivers

8.3 Polycystic Ovary Syndrome (PCOS) Drugs Market Challenges

8.4 Polycystic Ovary Syndrome (PCOS) Drugs Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Sanofi

Novartis

Teva Pharmaceutical Industries Limited

Addex Therapeutics Ltd

BIOCAD

Merck KGaA

Astrazeneca plc

Bristol-Myers Squibb Co

Ferring Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Inc

List of Tables

Table 1. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs) of Key Manufacturers (2019-2024)

Table 5. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Polycystic Ovary Syndrome (PCOS) Drugs Average Price (USD/Pcs) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Polycystic Ovary Syndrome (PCOS) Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Polycystic Ovary Syndrome (PCOS) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Polycystic Ovary Syndrome (PCOS) Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region (2019-2024) & (K Pcs)

Table 18. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region (2025-2030) & (K Pcs)

Table 20. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2019-2024) & (K Pcs)

Table 27. North America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2025-2030) & (K Pcs)

Table 28. North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2019-2024) & (K Pcs)

Table 32. Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2025-2030) & (K Pcs)

Table 33. Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region (2019-2024) & (K Pcs)

Table 37. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region (2025-2030) & (K Pcs)

Table 38. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2019-2024) & (K Pcs)

Table 42. Latin America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2025-2030) & (K Pcs)

Table 43. Latin America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2019-2024) & (K Pcs)

Table 47. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2025-2030) & (K Pcs)

Table 48. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs) by Type (2019-2024)

Table 51. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs) by Type (2025-2030)

Table 52. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Polycystic Ovary Syndrome (PCOS) Drugs Price (USD/Pcs) by Type (2019-2024)

Table 59. Global Polycystic Ovary Syndrome (PCOS) Drugs Price (USD/Pcs) by Type (2025-2030)

Table 60. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs) by Application (2019-2024)

Table 61. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs) by Application (2025-2030)

Table 62. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Polycystic Ovary Syndrome (PCOS) Drugs Price (USD/Pcs) by Application (2019-2024)

Table 69. Global Polycystic Ovary Syndrome (PCOS) Drugs Price (USD/Pcs) by Application (2025-2030)

Table 70. Sanofi Corporation Information

Table 71. Sanofi Description and Business Overview

Table 72. Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 73. Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 74. Sanofi Recent Developments/Updates

Table 75. Novartis AG Corporation Information

Table 76. Novartis AG Description and Business Overview

Table 77. Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 78. Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 79. Novartis AG Recent Developments/Updates

Table 80. Teva Pharmaceutical Industries Limited Corporation Information

Table 81. Teva Pharmaceutical Industries Limited Description and Business Overview

Table 82. Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 83. Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 84. Teva Pharmaceutical Industries Limited Recent Developments/Updates

Table 85. Addex Therapeutics Ltd. Corporation Information

Table 86. Addex Therapeutics Ltd. Description and Business Overview

Table 87. Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 88. Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 89. Addex Therapeutics Ltd. Recent Developments/Updates

Table 90. BIOCAD Corporation Information

Table 91. BIOCAD Description and Business Overview

Table 92. BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 93. BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 94. BIOCAD Recent Developments/Updates

Table 95. Merck KGaA Corporation Information

Table 96. Merck KGaA Description and Business Overview

Table 97. Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 98. Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 99. Merck KGaA Recent Developments/Updates

Table 100. AstraZeneca plc. Corporation Information

Table 101. AstraZeneca plc. Description and Business Overview

Table 102. AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 103. AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 104. AstraZeneca plc. Recent Developments/Updates

Table 105. Bristol Myers Squibb Co. Corporation Information

Table 106. Bristol Myers Squibb Co. Description and Business Overview

Table 107. Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 108. Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 109. Bristol Myers Squibb Co. Recent Developments/Updates

Table 110. Ferring Pharmaceuticals, Inc. Corporation Information

Table 111. Ferring Pharmaceuticals, Inc. Description and Business Overview

Table 112. Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 113. Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 114. Ferring Pharmaceuticals, Inc. Recent Developments/Updates

Table 115. Crinetics Pharmaceuticals, Inc. Corporation Information

Table 116. Crinetics Pharmaceuticals, Inc. Description and Business Overview

Table 117. Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 118. Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product

Table 119. Crinetics Pharmaceuticals, Inc. Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Polycystic Ovary Syndrome (PCOS) Drugs Distributors List

Table 123. Polycystic Ovary Syndrome (PCOS) Drugs Customers List

Table 124. Polycystic Ovary Syndrome (PCOS) Drugs Market Trends

Table 125. Polycystic Ovary Syndrome (PCOS) Drugs Market Drivers

Table 126. Polycystic Ovary Syndrome (PCOS) Drugs Market Challenges

Table 127. Polycystic Ovary Syndrome (PCOS) Drugs Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Polycystic Ovary Syndrome (PCOS) Drugs

Figure 2. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Share by Type in 2023 & 2030

Figure 4. Oral Contraceptives Product Picture

Figure 5. Antiandrogens Product Picture

Figure 6. Insulin-Sensitizing Agent Product Picture

Figure 7. Antidepressant Product Picture

Figure 8. Anti-Obesity Product Picture

Figure 9. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 10. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Share by Application in 2023 & 2030

Figure 11. Hospital

Figure 12. Clinic

Figure 13. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size (2019-2030) & (US$ Million)

Figure 15. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales (2019-2030) & (K Pcs)

Figure 16. Global Polycystic Ovary Syndrome (PCOS) Drugs Average Price (USD/Pcs) & (2019-2030)

Figure 17. Polycystic Ovary Syndrome (PCOS) Drugs Report Years Considered

Figure 18. Polycystic Ovary Syndrome (PCOS) Drugs Sales Share by Manufacturers in 2023

Figure 19. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Manufacturers in 2023

Figure 20. The Global 5 and 10 Largest Polycystic Ovary Syndrome (PCOS) Drugs Players: Market Share by Revenue in 2023

Figure 21. Polycystic Ovary Syndrome (PCOS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 22. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Country (2019-2030)

Figure 24. North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Country (2019-2030)

Figure 25. U.S. Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Country (2019-2030)

Figure 28. Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Country (2019-2030)

Figure 29. Germany Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Region (2019-2030)

Figure 36. China Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Taiwan Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Indonesia Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Thailand Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Malaysia Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Philippines Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Latin America Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Country (2019-2030)

Figure 47. Latin America Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Country (2019-2030)

Figure 48. Mexico Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Brazil Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Argentina Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Country (2019-2030)

Figure 52. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Country (2019-2030)

Figure 53. Turkey Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Saudi Arabia Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. UAE Polycystic Ovary Syndrome (PCOS) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 56. Global Sales Market Share of Polycystic Ovary Syndrome (PCOS) Drugs by Type (2019-2030)

Figure 57. Global Revenue Market Share of Polycystic Ovary Syndrome (PCOS) Drugs by Type (2019-2030)

Figure 58. Global Polycystic Ovary Syndrome (PCOS) Drugs Price (USD/Pcs) by Type (2019-2030)

Figure 59. Global Sales Market Share of Polycystic Ovary Syndrome (PCOS) Drugs by Application (2019-2030)

Figure 60. Global Revenue Market Share of Polycystic Ovary Syndrome (PCOS) Drugs by Application (2019-2030)

Figure 61. Global Polycystic Ovary Syndrome (PCOS) Drugs Price (USD/Pcs) by Application (2019-2030)

Figure 62. Polycystic Ovary Syndrome (PCOS) Drugs Value Chain

Figure 63. Polycystic Ovary Syndrome (PCOS) Drugs Production Process

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Distributors Profiles

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions